Israel-based company Nevia Bio, formerly known as Gina Life, has raised USD 3.1 million in a seed funding round led by MindUP Digital Health Incubator, with participation from Pitango HealthTech, Alive Israel HealthTech Fund, the Technion investment arms, and other existing investors. This brings a total fund of USD 5 million.
The funding will be used to advance clinical trials for its lead ovarian cancer program, which decodes biomarker data from vaginal secretions for early detection. It will also support the broadening of the range of solutions in women's health and strengthen the company's capabilities in data science.
Nevia is a FemTech company that has developed a platform designed to interpret biomarker data found in vaginal secretions. The company uses machine learning and data science techniques to identify unique biomarkers, which enable the early detection of diseases affecting women.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.